Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin holds near $82K despite $230M ETF outflows and continued exchange selling

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin holds near $82K despite $230M ETF outflows and continued exchange selling

Bitcoin traded near $82,000 on Oct. 19 as on-chain data showed increased capital inflows, despite $230 million outflows from U.S. spot Bitcoin ETFs and ongoing selling on exchanges. Short-term, price-sensitive capital and new holders rose, indicating fresh investment entering Bitcoin. However, spot trading remained seller-dominated, with net selling increasing and futures selling easing but still negative. Network activity softened slightly, with lower transaction fees and transfer volume, while the share of Bitcoin held at a profit declined. This mixed picture suggests cautious investor sentiment amid active market dynamics.

Bitcoin capital inflows and U.S. spot ETF outflows provide context for this market snapshot. For readers following cryptocurrency trends, here is Pluang's market data as of Oct 20, 2026 06:02 WIB: Among 50 major cryptocurrencies, 42 rose and 7 fell today. BAL (Balancer) led with a 1-day increase of 11.14% at Rp16.297, surpassing EOS (EOS.IO) which rose 8.13% to Rp12.649, while CRV (Curve DAO Token) showed a 7.85% gain at Rp6.647 but had a dominant sell order activity of 99% on Pluang.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
26 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
26 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App